LDS/Medical Tests/Stool Nucleic Acid Based Colorectal Cancer Screening Test, Cologaurd®, Cologuard Plus, ColoSense

Stool Nucleic Acid Based Colorectal Cancer Screening Test, Cologaurd®, Cologuard Plus, ColoSense

Colorectal cancer (CRC) is the third most common diagnosed cancer and the second leading cause of cancer-related deaths in men and women. Early detection is very important for disease management. Publication show that if detected in early localized stage, the five-year survival rate is above 90%, if detected when there has been local progression to regional tissues, five-year survival is as high as 70%. However, if detected late, after the cancer has spread to distant organs/tissues, five-year survival drops below 15%. Therefore, screening for CRC is important and has been supported by published recommendations and guidelines.

Four types of test are currently available for CRC detection or screening, including fecal-based occult blood test (FOBT or FIT), tumor marker blood test, combined fecal DNA and FIT test, and imaging (colonoscopy).

Cologuard is a fecal immune-occult blood and DNA screening test performed on stool. It qualitatively detects DNA markers associated with CRC as well as human blood. A positive result can be associated with either colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. The test is intended to screen adults of either sex, 50 years or older, who are at average-risk for CRC.

Specifically, Cologuard is designed to detect three (3) independent categories of biomarkers that exhibit an additive association with CRC and AA. The first category of biomarkers targets epigenetic changes in the form of gene promoter region methylation. The specific methylated gene targets include N-Myc Downstream-Regulated Gene 4 (NDRG4) and Bone Morphogenetic Protein 3 (BMP3). The second category targets seven (7) specific gene mutations in V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS). The third biomarker is non-DNA based and detects occult human hemoglobin. Additionally, the test utilizes beta-actin (“ACTB”) as a reference gene used for confirmation and quantitative estimation of the total amount of human DNA present in each sample. Results from the methylation, mutation, and hemoglobin assays are integrated by the Exact Sciences Analysis Software to determine a Positive or Negative reportable result or invalid result. The test has a reported 92% sensitivity and 87% specificity. It must be remembered that FIT testing is performed annually compared to Cologuard which is every three years. With those testing frequencies the FIT test shows comparable sensitivity and higher specificity (5% false positives) compared to Cologuard and is significantly less expensive.

In 2024 Exact Sciences received FDA approval for its Cologuard Plus test, a next-generation multitarget stool DNA test that enhances colorectal cancer and precancerous lesion detection in adults 45 and older at average risk.

The next generation test incorporated a new molecular panel (including the methylated DNA markers ceramide synthase 4 gene (LASS4), leucine-rich repeat-containing protein 4 gene (LRRC4), serine–threonine protein phosphatase 2A 56-kDa regulatory subunit gamma isoform gene (PPP2R5C), and the reference marker zinc finger DHHC-type containing 1 gene (ZDHHC1), while retaining fecal hemoglobin.

The Cologuard Plus test showed 95% cancer sensitivity and 43% sensitivity for advanced precancerous lesions with 94% specificity, based on findings from the pivotal BLUE-C study.

ColoSense is a qualitative in vitro diagnostic test intended for the detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco Immunochemical Fecal Occult Blood Test (iFOBT) Analyzer; bioMerieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx Droplet Digital Polymerase Chain Reaction (ddPCR) System. ColoSense is a single-site test performed at Geneoscopy, Inc.

ColoSense is designed to analyze patients’ stool for the presence of 8 RNA molecular biomarkers (GAPDH, ACY1, AREG, TNFRSF10B, CDH1, EGLN2, KRAS, SMAD4) and hemoglobin, supplemented with patient smoking status, which together may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL).

A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA) or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

  • Screening and early detection of colorectal cancer in patient who are defined as having average risk of colorectal cancer
  • Screening test for adults, 45 years of age or older, who are at average-risk for developing CRC.
Positive results can indicate the presence of colorectal cancer or advance adenoma (pre-cancer). Results should be correlated with other screening or diagnostic tests such as colonoscopy.

Negative Negative results indicate lower likelihood that colorectal cancer or advance adenoma is present.

Quantitative Allele-Specific Real-time Target and Signal (QuARTS™) amplification. The QuARTS™ amplification technology combines the routinely used molecular biology techniques of real-time PCR and invasive cleavage chemistry to perform allele-specific amplification and detection of methylated target DNA (NDRG4, BMP3), specific DNA point mutations (KRAS) and total human DNA (ACTB). Quantitative ELISA technique is used to analyze the level of hemoglobin present in the stool sample.

Stool samples are collected using the Cologuard Collection Kit, which includes patient instructions, a protein sample tube with stool collection stick and buffer, a stool collection container, a foldable plastic bracket, a liquid preservative, and a mailing container. The mailing container is used to send the collected sample to a lab for processing.

Colon Cancer Multi-Gene Panel by NGS, Cancer Antigen (CA) 19-9, Colon Biopsy, KRAS Gene Mutation Analysis, Microsatellite Instability (MSI), Carcinoembryonic Antigen (CEA).

1-3 weeks. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login